(Q27853059)

English

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

PubMed publication ID

13 November 2016

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. (English)

1 reference

PubMed publication ID

13 November 2016

0 references

0 references

1 reference

based on heuristic

inferred from title

brain metastasis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Sai-Hong Ignatius Ou

17

object named as

Sai-Hong Ignatius Ou

0 references

object named as

Leena Gandhi

2

0 references

author name string

Shirish M Gadgeel

1

0 references

Gregory J Riely

3

0 references

Alberto A Chiappori

4

0 references

Howard L West

5

0 references

Michele C Azada

6

0 references

Peter N Morcos

7

0 references

Ruey-Min Lee

8

0 references

Linta Garcia

9

0 references

Li Yu

10

0 references

Frederic Boisserie

11

0 references

Laura Di Laurenzio

12

0 references

Sophie Golding

13

0 references

Jotaro Sato

14

0 references

Shumpei Yokoyama

15

0 references

Tomohiro Tanaka

16

0 references

publication date

September 2014

0 references

language of work

Lancet Oncology Commission

0 references

15

0 references

10

0 references

1119-28

0 references

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ceritinib in ALK-rearranged non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970362-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70362-6

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853059&oldid=1541401662"